

# Gunderson Dettmer Advises City Therapeutics in \$1 Billion Strategic Collaboration with Biogen to Advance RNAi Therapies

Client News

May 27, 2025

Gunderson Dettmer represented client [City Therapeutics](#), a Cambridge-based biopharmaceutical company pioneering RNA interference (RNAi)-based medicine, in its \$1 billion strategic collaboration with Biogen Inc., a company focused on pioneering innovative science to deliver new medicines. City Therapeutics will leverage its next-generation RNAi engineering technologies alongside Biogen's proprietary drug delivery platform to develop novel RNAi therapies targeting central nervous system diseases. The collaboration will initially focus on a single disease target, with the potential to expand to additional programs.

In the [announcement of the collaboration](#), CEO of City Therapeutics Andy Orth said, "Partnering with Biogen represents a meaningful milestone in our mission to expand the therapeutic reach of RNAi, as we pioneer the next generation of RNAi technology for breakthrough medicines. By combining our novel RNAi platform with Biogen's industry-leading capabilities in global drug development, we aim to accelerate the advancement of therapies for serious diseases. We look forward to demonstrating the potential of our RNAi platform in addressing this area of significant unmet need."

The Gunderson deal team was led by Brendan McCarthy and Shu Hu.

Companies

[City Therapeutics](#)

## Related People



Brendan C. McCarthy

PARTNER

P +1 858 436 8013



Shu Hu

OF COUNSEL

P +1 650 463 5329

## Related Services

Early-Stage Company

Life Sciences

Life Sciences Licensing & Strategic Partnering

Private & Public Companies

UK and Europe

# Featured Insights

## EVENTS

Webinar: From Launch to Scale: Building a Strong Operational Foundation for Emerging Fund Managers

## EVENTS

Webinar: Private Fund Focus Part II: Alternative Strategies for Unlocking LP Liquidity

## EVENTS

Webinar: Private Fund Focus Part I: Liquidity Strategies and Secondary Transactions

## EVENTS

Webinar: Private Company Focus: Trends and Insights on Tender Offers for Venture-Backed Companies

## EVENTS

Webinar: AI Notetakers: Risks and Considerations for Funds

## CLIENT NEWS

Gunderson Dettmer Advised Hims & Hers in its Inaugural \$175 Million Senior Secured Revolving Credit Facility

## INSIGHTS

BRAVE Southeast Asia Podcast: E-Fishery Scandal Breakdown, Investor Red Flags & Legal Risk Lessons for Southeast Asia

## CLIENT NEWS

David AI Announces \$25M Series A Financing

## FIRM NEWS

Gunderson Dettmer Wins Best Technology Deal in 2025 Mergers & Acquisitions Top Middle-Market Awards

## CLIENT NEWS

Point72 Leads \$31M Series A of Defense Tech CX2

## CLIENT NEWS

Axle Health Announces \$10M Series A to Advance Home Health Operations

## CLIENT NEWS

BRIK Announces \$10M Series A Funding